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Abstract 
Background: Despite its clinical relevance, cerebral amyloid angiopathy (CAA) is 
underdiagnosed worldwide. This retrospective study aimed to assess the incidence, etiology, 
predictors, and outcome of intracerebral hemorrhages (ICHs) in this region, with special focus 
on possible underlying CAA. 
Methods: Database screening of acute cares with intracranial hemorrhage diagnosis within 
01/07/2014–01/07/2018 were conducted, analyzing medical records and imaging. Spontaneous 
ICHs were classified as deep (basal ganglionic/thalamic/brainstem) and lobar/cerebellar (i.e., 
CAA-compatible) ICHs. Probable/definite CAA was established using the modified Boston 
criteria in a subgroup with ‘complete’ radiological/neuropathological work-up. The ability of 
several factors to discriminate between deep and lobar/cerebellar ICHs, between 
probable/definite CAA and non-probable CAA cases, and to predict 1-month case fatality was 
assessed. 
Results: Of the 213 ICHs identified, 121 were in deep and 92 in lobar/cerebellar localization. 
Sub-analysis of 47 lobar/cerebellar ICHs with ‘complete’ work-up identified 16 
probable/definite CAA patients, yielding an estimated 14.7% prevalence of CAA-related ICHs. 
Chronic hypertension was the most prevalent risk factor for all types of ICHs (including CAA-
related), with hypertensive excess and younger age being independent predictors of deep 
whereas antiplatelet use of lobar/cerebellar localization. The 1-month case fatality was 33.8%, 
driven predominantly by age and INR>1.4. Probable/definite CAA diagnosis was 
independently predicted by age, prior intracranial hemorrhage, and antiplatelet use. 
Conclusions: First in this region and among the few in the literature, this study reports a 
remarkable prevalence of CAA-related ICHs, emphasizing the need for an increased awareness 
of CAA and its therapeutic implications, especially regarding antiplatelets among the elderly. 
Keywords: cerebral amyloid angiopathy, epidemiology, intracerebral hemorrhage, lobar, 
predictor.  
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Introduction 
Stroke is one of the leading causes of death and disability globally. After ischemic 
stroke, intracerebral hemorrhage (ICH) is the second most prevalent type, accounting for some 
10% of all cases (Feigin et al. 2009). The most common known risk factors of spontaneous 
ICHs include advanced age, chronic hypertension, cerebral amyloid angiopathy (CAA), alcohol 
and drug abuse, and antithrombotic medications (Aguilar and Brott 2011). Recent studies 
further highlight the role of systemic inflammation in determining ICH propagation and 
outcome, and implicate the potential protective role of substances with anti-inflammatory 
properties (Di Napoli et al. 2014; Di Napoli et al. 2016). 
Based on etiological considerations, ICHs are commonly classified into deep ICHs (i.e., 
originating from blood vessels in the basal ganglia, thalamus, or brainstem), predominantly 
associated with chronic hypertension/hypertensive arteriopathy, and lobar ICHs, which are 
most frequently related to CAA and, relatively less frequently, to other etiologies such as 
vascular malformations or tumors (Ikram et al. 2012). The distribution of cerebral microbleeds 
(CMBs) follows a similar anatomical pattern, with chronic hypertensive (a.k.a. hyaline) 
arteriopathy associating primarily with CMBs in deep localizations and CAA typically 
associating with lobar CMBs, sparing the deep structures (Greenberg et al. 2009). Of note, 
cerebellar ICHs and CMBs can be attributable to either chronic hypertensive arteriopathy or 
CAA (Greenberg and Charidimou 2018); therefore, their classification in the literature is not 
unequivocal, some authors classifying them as deep (Labovitz et al. 2005) or non-lobar (Zia et 
al. 2007; Samarasekera et al. 2015) while others omitting them from analyses (Falcone et al. 
2013), analyzing them separately (Samarasekera et al. 2012), or using alternative classifications 
(Gregoire et al. 2010). 
In CAA, cortical and leptomeningeal small arteries/arterioles and capillaries are 
degenerated due to the progressive deposition of β-amyloid peptides, associating with both 
CAA-related ischemic alterations (including microinfarctions and leukoaraiosis) and different 
types of hemorrhages (including CMBs and ICHs in lobar (and cerebellar) localization, and 
cortical superficial siderosis (CSS, a.k.a. convexity subarachnoid hemmorhage (SAH))) 
(Yamada 2015). 
Clinical manifestations of CAA can be various, ranging from asymptomatic stage to 
fatal ICHs. Typically, CAA-related ICHs are recurrent and cause various neurological deficits 
(depending on localization), headache, and epileptic seizures with or without loss of 
consciousness (Yamada 2015). Patients usually develop slowly progressive cognitive 
impairment due to multiple CMBs and microinfarctions (i.e., vascular neurocognitive disorder 
or mixed-type neurocognitive disorder, in the presence of concomitant Alzheimer’s disease 
(AD) pathology). In addition, CAA patients frequently experience transient ischemic attack 
(TIA)-like events, a.k.a. transient focal neurological episodes (TFNEs) or ‘amlyoid spells’; 
these events are, however, presumed to be due to focal epileptic activity secondary to CSS and 
not thrombotic in origin (Yamada 2015). 
Magnetic resonance imaging (MRI) sequences sensitive to susceptibility artefacts 
generated by hemosiderin deposits of previous micro- and macrobleeds, such as gradient echo 
(GRE), susceptibility-weighted imaging (SWI), or T2* sequences, in addition to a set of clinical 
characteristics, make it possible to establish a probabilistic diagnosis of CAA in vivo with high 
diagnostic accuracy (Greenberg and Charidimou 2018). The original Boston criteria was 
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modified in 2010 recognizing CSS as part of CAA-related alterations (Linn et al. 2010). This 
Modified Boston criteria (with increased sensitivity and retained specificity) enables 
establishing the diagnosis of possible CAA and probable CAA without histological 
confirmation (i.e., biopsy specimen or post mortem tissue) in patients above 55 years, with the 
presence of a single hemorrhagic alteration (ICH, CMB, or CSS) in lobar localization without 
other cause allowing the diagnosis of possible CAA, and >1 of such hemorrhagic alterations 
without other cause meeting the diagnosis of probable CAA (Linn et al. 2010). While deep 
(basal ganglionic, thalamic, and brainstem) hemorrhagic alterations preclude the diagnosis of 
both possible and probable CAA, cerebellar bleeds are allowed, albeit not counted for the 
diagnosis (Greenberg and Charidimou 2018). Definite CAA diagnosis can be established only 
via full post mortem histological investigation. 
CAA is by no means infrequent. Affecting some 5% of the population over 65 years of 
age (Biffi and Greenberg 2011), its prevalence is comparable to that of AD (Lobo et al. 2000) 
(with which it shows some 70-80% overlap (Jellinger 2002; Brenowitz et al. 2015)) and atrial 
fibrillation (AF) (Majeed et al. 2001). Though curative therapy is lacking, the clinical relevance 
of the diagnosis is high. Indeed, the use of anticoagulants is contraindicated in CAA according 
to current guidelines due to a 7-10-fold increase in the risk of ICH (Kernan et al. 2014; 
Heidbuchel et al. 2015). The use of antiplatelet therapy should also be carefully considered in 
CAA, due to an up to 4-fold increase in the risk of recurrent ICH in general population after 
lobar ICH (Biffi et al. 2010) and a 2-fold prevalence of lobar CMBs in patients suffering ICH 
while on antiplatelet therapy (Gregoire et al. 2010). Though prior ICH has always been an 
absolute contraindication for systemic thrombolysis in acute ischemic stroke, a >10 CMB 
number per se has recently been introduced as a contraindication due to uncertain benefit 
(Powers et al. 2018). Despite the high prevalence and relevance among the elderly, the 
establishment of a clinical diagnosis of CAA to our experience has been sporadic. Based on the 
discrepancy between the expected frequency of CAA among the elderly and the experienced 
occurrence of CAA diagnosis in the routine clinical practice, our aim was to asses the frequency 
of the different types of spontaneous ICHs observed in our stroke center with special focus on 
estimating the underlying prevalence of CAA, by means of the retrospective re-evaluation of 
written and imaging documentation. Emphasis was given on the analysis of the predictive value 
of putative risk factors for ICH location, probable/definite CAA diagnosis, and fatal outcome. 
 
Materials, patients, and methods 
Via screening the electronic database, patients who received acute in-patient care in our 
center between 01/07/2014 and 01/07/2018 with any of the intracranial hemorrhage-related 
International Classification of Diseases (ICD) diagnosis codes were identified. Reviewing the 
imaging scans and medical records, spontaneous ICHs were separated from intracranial 
hemorrhages with traumatic etiology, cases with SAH, primary intraventricular hemorrhage, 
and hemorrhagic transformation of ischemic stroke, and from cases with inadequate coding. 
Spontaneous ICHs were further classified according to hematoma localization as deep ICHs 
(basal ganglia, thalamus, or brainstem) and lobar/cerebellar ICHs (regions compatible with the 
diagnosis of probable CAA, enabling the estimation of the prevelance of underlying CAA). 
The prevalence of different etiologies behind lobar/cerebellar ICHs was assessed in a 
subpopulation who underwent ‘complete’ clinical work-up, defined as being subjected to 
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computed tomography angiography (CTA) or magnetic resonance angiography (MRA) as well 
as MRI-SWI (if structural etiology was not identified by angiography) and/or post mortem 
neuropathological work-up. Definite CAA, probable CAA, and possible CAA diagnoses were 
retrospectively established or revised as per the Modified Boston criteria (Linn et al. 2010). An 
ICH was considered CAA-related if met the criteria for probable and/or definite CAA. 
Clinical data collected about the patients included their age at the time of ICH, sex, 
history of intracranial vascular events (including TIA, clinical episode of ischemic or 
hemorrhagic stroke), family history of any stroke, prior episodes of loss of consciousness, 
chronic hypertension, hypertensive excess at presentation (defined as ≥180 mmHg systolic 
blood pressure), current use of antiplatelet and/or anticoagulant drugs, as well as the 
international normalized ratio (INR) values on admission for ICH. Case fatality (lethality) was 
defined as fatal outcome within 1 month secondary to the ICH event in the absence of evidence 
for unrelated cause of death (e.g., cardiac arrest). 
For statistical analysis, the SPSS 20.0 software (IBM Corp., Armonk, New York, USA; 
RRID:SCR_002865) was used. For comparative assessment of continuous variables, 
parametric (Student t) or non-parametric (Mann-Whitney U) tests were used after normality 
analysis with the Shapiro-Wilk test. For comparative analysis of discrete variables, cross-
tabulation analysis was used by the Chi2 test, applying Fisher’s exact values when appropriate. 
Backward conditional multivariate binary logistic regression analyses were used to assess the 
effect of predictors found to be significant in the univariate comparative analyses. The binary 
outcomes were deep ICHs vs. lobar/cerebellar ICHs, case fatality at 1 month vs. alive at 1 
month, and probable/definite CAA vs. non-probable CAA (including all deep ICHs and the 
subgroup of lobar/cerebellar ICH with ‘complete’ clinical work-up not meeting the criteria for 
probable/definite CAA). The level of significance was p<0.05. Data within the text are 
presented as mean±standard error of the mean (SEM) or median [interquartile range] in the 
cases of normal or non-normal distribution, respectively. 
 
Results 
Revision of diagnoses, estimation of CAA-related ICH prevalence 
A total of 324 patients having received any intracranial hemorrhage-related ICD codes as 
leading diagnosis in the given period were identified. After exclusions, 213 spontaneous ICHs 
were identified (Fig. 1). Among spontaneous ICHs, 121 deep ICHs (110 (51.6%) localized to 
the basal ganglia/thalamus and 11 (5.2%) to the brainstem) and 92 lobar/cerebellar ICHs (85 
(39.9%) localized to any cerebral lobe and 7 (3.3%) to the cerebellum) were detected (Fig. 2a). 
Out of lobar/cerebellar ICHs, 47 had ‘complete’ clinical work-up, of whom 2 proved to 
be definite CAA post mortem (Online Resource 1) and 14 were consistent with the diagnosis 
of probable CAA clinically (Fig. 3; one of them also became definite post mortem), rendering 
(16/47) 34.0% of all ‘completely’ worked-up lobar/cerebellar ICHs and (considering this rate 
as representative for all lobar/cerebellar ICHs) an estimated 14.7% of all spontaneous ICHs to 
be CAA-related. CMBs were present in 92.9% of probable CAA cases, with 42.9% having >10 
CMBs, whereas CSS was present in 78.6%, with 57.1% of probable CAA cases having diffuse 
CSS.  In addition, 10 patients met the criteria for possible CAA, and another 5 patients would 
have also meet criteria for probable (1) and possible CAA (4) except for their age being under 
55. In 12 cases (25.5%), structural (i.e., secondary) etiologies such as arteriovenous 
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malformation, ruptured aneurysm, sinus thrombosis, dural arteriovenous fistula or metastatic 
tumor were detected, whereas 4 cases (8.5%) were consistent with hypertensive arteriopathy 
(Fig. 2b). Out of the 14 probable CAA cases identified, originally only 4 had received CAA at 
least as suspected diagnosis (28.6%). 
 
Analysis of possible discriminators of ICH subgroups  
The median age of the 213 patients with spontaneous ICH was 69.1 [60.3–79.0] years, 
with the lobar/cerebellar ICH group being significantly older compared to deep ICHs (74.5 
[65.9–82.0] vs. 64.7 [57.9–76.6] years; p<0.001; Table 1). 
The distribution of sex was significantly different between deep and lobar/cerebellar ICH 
groups (p=0.029), with a remarkable male preponderance in deep ICHs (66.9%) and a close to 
even ratio in lobar/cerebellar ICHs. 
The frequency of prior episode(s) of TIA (TFNE), ischemic stroke, intracranial 
hemorrhage, and loss of consciousness in all ICHs were 10.5%, 12.4%, 8.1%, and 8.1%, 
respectively, being comparable between deep and lobar/cerebellar ICH groups. 
The family history for either ischemic or hemorrhagic stroke (specification was not 
possible) was positive in 32.5%, with no between-group difference. 
A total of 16.7% of ICH cases were on anticoagulant therapy at presentation, 74.3% 
because of AF. Three-quarter (77.1%) of anticoagulated patients were on a vitamin K antagonist 
(VKA; warfarin (4/27) or acenocoumarol (23/27)), 88.9% of whom had an INR>1.4 at 
presentation. Two patients were on rivaroxaban, one on apixaban, together making up 8.6% of 
anticoagulated patients, while other direct oral anticoagulants (DOACs) were not represented. 
In 5 patients (14.3%), different doses of low-molecular-weight heparin (LMWH) were used. 
The frequency of anticoagulant use at presentation was comparable between ICHs in deep and 
lobar/cerebellar localizations. Notably, out of the 7 lobar/cerebellar ICH patients with a positive 
history of intracranial hemorrhage, 3 were on therapeutic anticoagulation, and 2 of them were 
on antiplatelet treatment as well. Antiplatelet use was present in 32.2%, with a significant 
preponderance in lobar/cerebellar (43.3%) compared to deep ICHs (23.7%; p=0.003). 
Altogether 7.7% of ICH patients were on combined antithrombotic regimen (on both 
anticoagulant and antiplatelet therapy), the significant majority (75.0%) suffering a 
lobar/cerebellar ICH (p=0.016). 
A total of 191 ICH patients were known for chronic hypertension (89.7%), which was the 
most prevalent risk factor for both deep and lobar/cerebellar ICHs, with no significant between-
group difference. On the other hand, 61.5% of ICH patients experienced hypertensive excess 
(systolic blood pressure >180 mmHg) at presentation, in a significantly higher rate in the deep 
compared to the lobar/cerebellar ICH group (71.2% vs. 48.9%, respectively, p=0.001). 
Analyzing the risk factors with significant between-group difference (age, sex, 
antiplatelet use, combined antithrombotic treatment, and hypertensive excess at presentation) 
in a multivariate binary logistic regression model revealed advanced age (p=0.014; odds ratio 
(OR)=1.03) and antiplatelet use (p=0.043; OR=1.96) to be statistically significant independent 
predictors of a lobar/cerebellar ICH, and hypertensive excess to be a strong significant 
independent predictor of deep ICH (p=0.002; OR=0.39). 
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Case fatality 
The 1-month case fatality of ICH patients was 33.8%, with no significant difference 
between deep and lobar/cerebellar ICH groups (Table 1). Significant determinants of 1-month 
case fatality in ICHs as a whole were age, prior TIA, current anticoagulant use, and INR>1.4 
in univariate comparisons, with only advanced age (p=0.003; OR=1.04) and INR>1.4 (p=0.035; 
OR=2.51) proven to be independent predictors of case fatality in multivariate analysis (Online 
Resource 2). 
 
Analysis of factors to predict CAA 
The probable/definite CAA subgroup had the highest mean age at ICH presentation 
(75.9±2.3 years), significantly higher compared to non-probable CAA patients (65.6±1.1 years; 
p=0.002). This was associated with a significant female predominance in probable/definite 
CAA (62.5%) as opposed to the male predominance (64.5%) in the comparator (p=0.035). 
Some 31.3% of probable/definite CAA cases had prior clinical event(s) of intracranial 
hemorrhage and exactly the same rate had prior TIA/TFNE, significantly higher than in the 
non-probable CAA group (6.8% (p=0.008) and 7.4% (p=0.010), respectively). 
The ratio of patients on antiplatelet (56.3%) within the definite/probable CAA subgroup 
was remarkably higher compared to non-probable CAA patients (25.2% (p=0.009)). 
Other factors and case fatality were not significantly different in the comparative 
analyses; of note, chronic hypertension was invariably prominent (Table 2). 
Multivariate analysis of factors significant in the univariate comparative analyses 
revealed older age (p=0.012; OR=1.08), prior intracranial hemorrhage (p=0.005; OR=8.53), 
and antiplatelet use (p=0.042; OR=3.45) as independent significant predictors of 
definite/probable CAA diagnosis. 
 
Discussion 
Aiming to assess the predictors and outcome of spontaneous ICHs of different 
localization with particular focus on the prevalence of underlying CAA, this study identified 
hypertensive excess and younger age as independent predictors of deep whereas antiplatelet use 
of lobar/cerebellar localization, age and INR>1.4 as indepenent predictors of 1-month case 
fatality, and age, prior intracranial hemorrhage, and antiplatelet use as independent predictors 
of probable/definite CAA diagnosis, in addition to an estimated prevelance of CAA-related 
ICHs comparable to prior publications. 
The timely identification of patients with probable CAA is imperative, as it is associated 
with serious therapeutic consequences, especially regarding the avoidance of 
antithrombotic/thrombolytic medications, with increasing literature demonstrating a higher risk 
of harm compared to benefit (Yamada 2015). Despite these, CAA is considered to be 
underdiagnosed worldwide, its epidemiology is largely based on neuropathological case series, 
and the prevalence of CAA among ICH patients (i.e., CAA-related ICH) with/without 
associated potential risk factors have only been addressed by a few studies on clinical grounds 
(Online Resource 3) (Meretoja et al. 2012; Yeh et al. 2014; Roh et al. 2018; Jamieson et al. 
2012; Palm et al. 2013). Consequently, our aim was to revise all spontaneous ICH cases in our 
center in a 4-year period, with special focus on identifying patients with probable/definite CAA, 
and analyzing associated risk factors and fatal outcome. 
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The 213 ICH cases detected represent an incidence of approximately 13.3/100,000 
persons/year, resembling the 12-15/100,000 persons/year reported in the U.S. (Aguilar and 
Brott 2011). In our study, 51.6% of spontaneous ICHs originated in the basal ganglia/thalamus, 
3.3% in the cerebellum, 5.2% in the brainstem, and 39.9% were of lobar localization. According 
to international data reporting 35-70%, 5-10%, 5-10%, and 15-30%, respectively (Aguilar and 
Brott 2011), this suggests a relative overrepresentation of lobar ICHs compared to expectations, 
highlighting the relevance and necessity of an increased awareness of CAA in this population. 
This ratio is similar to Swedish and U.S. findings with 43.2% and 40.5% rates of lobar ICHs, 
respectively (Zia et al. 2007; Broderick et al. 1993). The analysis of risk factors confirmed ICH 
as the disease of the elderly (the median 69.1 years being consistent with previous reports 
(O'Donnell et al. 2010)). In particular, older age proved to be an independent predictor of 
lobar/cerebellar (i.e., CAA-compatible) ICH localization, resembling findings for lobar ICHs 
(Labovitz et al. 2005; Matsukawa et al. 2012; Weimar et al. 2011). Hypertension was by far the 
most common coexistent factor (~90%) irrespective of ICH localization. Identifying 
hypertension as primary risk factor for ICHs is consistent with international meta-analyses 
(Ikram et al. 2012; O'Donnell et al. 2010; Ariesen et al. 2003); however, its prevalence was 
higher than in many individual studies (Zia et al. 2007; Yeh et al. 2014; Broderick et al. 1993), 
albeit similar to some reports from Europe (Smajlovic et al. 2008; Safatli et al. 2016). Despite 
the concept that chronic hypertension would associate more with deep ICHs, our results 
emphasize that it is essentially present in any subtypes of ICHs (in line with some prior 
observations (Broderick et al. 1993)) and only an extreme hypertension around the event 
demonstrated to be a significant (in fact the strongest) predictor of deep ICHs. Male sex, a factor 
frequently reported as a risk for ICH (Labovitz et al. 2005; Ariesen et al. 2003; van Asch et al. 
2010), was also slightly overrepresented in the pooled cohort (60.6%), driven, however, entirely 
by deep ICHs (66.9%), with the sex rate of lobar/cerebellar ICHs being ~50%, recapitulating 
prior observations (Labovitz et al. 2005; Zia et al. 2007; Yeh et al. 2014). The use of 
antithrombotics were frequent (41.1%), with antiplatelet use proven to be an independent 
predictor of lobar/cerebellar ICH localization. The results were practically identical when using 
the traditional lobar vs. non-lobar comparison (Online Resource 4). 
The 1-month case fatality of all ICHs was 33.8%, with no significant effect of 
localization. This rate is consistent with a previous report from this region (Ovary et al. 2004) 
and similar to reports from U.S. (Labovitz et al. 2005), being somewhat favorable compared to 
international median of 40.4% in a recent meta-analysis (van Asch et al. 2010). The 
identification of age as an independent decisive factor recapitulates this meta-study (van Asch 
et al. 2010). Though resembling findings of SMASH-U studies for medication-related ICHs 
(Meretoja et al. 2012; Yeh et al. 2014), the independent prognostic value of admission INR>1.4 
(but not of anticoagulant use per se in the multivariate analysis) is a novelty (reported previously 
only in primary lobar ICHs (Falcone et al. 2013)), giving an additional context to the risk posed 
by anticoagulants, particularly VKAs. 
The analysis of potential clinical predictors of CAA-related ICHs revealed older age 
(~8% increase in risk per year) and prior intracranial hemorrhage (~8.5-fold risk) as 
independent significant predictors of probable/definite CAA diagnosis, which is consistent with 
the notion that CAA is the disease of the elderly (Yamada 2015) and CAA-related ICHs are 
often recurrent (Biffi and Greenberg 2011). These, together with the female predominance in 
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probable/definite CAA (though proven to be not independent of age) recapitulate key 
observations of a recent study from the U.S. comparing their probable/definite CAA-related 
ICH group with hypertension-related ICHs (as per SMASH-U) (Roh et al. 2018), and concord 
with autopsy studies demonstrating female predominance in CAA-related ICHs (Attems et al. 
2008; Hirohata et al. 2010). 
Highlighting its primary role in ICH development irrespective of etiology, our data 
indicates that pre-existing hypertension is invariably associated with definite/probable CAA 
diagnosis (93.8%), with the prevalence of hypertensive excess at presentation (46.7%) not being 
significantly different from the comparator group either. 
Though significant only at the univariate level, a remarkably high rate of definite/probable 
CAA patients (31.3%) had experienced prior ‘TIA’ compared to non-probable CAA (7.4%), 
presumably representing ‘amyloid spells’, suggested to be of epileptic origin. Interpreting these 
events as ‘ischemic’ necessarily adds to the inherited risk of ICH in CAA, due to the consequent 
initiation of antiplatelet therapy. Indeed, antiplatelet and anticoagulant drugs are considered a 
risk for ICH in CAA. Our study concords with this, revealing 68.8% of ICH patients with 
definite/probable CAA to be under at least one type of antithrombotic medication, with the 
multivariate analysis identifying antiplatelet (but not anticoagulant) use as an independent 
predictor of probable/definite CAA diagnosis. The 3.3-times higher prevalence of 
probable/definite CAA diagnosis in antiplatelet users vs. non-users resembles the 2-fold 
prevalence of lobar microbleeds in antiplatelet user ICH patients in a previous study (Gregoire 
et al. 2010). 
Underlying the relevance of missed diagnoses, a patient with fatal CAA-related ICH was 
on combined antithrombotic therapy despite a prior lobar ICH 1 year before the index ICH, 
having an SWI scan at first ICH already consistent with probable CAA, retrospectively. 
Our study has a number of limitations, including its retrospective nature, resulting in a 
certain amount of random missing values regarding some clinical factors analyzed, decreasing 
their statistical power. Strengths include the relatively large subject number, to our knowledge 
being among the largest studies reporting multivariate binary analysis of clinical discriminators 
of ICH localization, overtaken by a study from Japan (Matsukawa et al. 2012) and Germany 
(Weimar et al. 2011). Additional strength is the unprecedented rigor that probable and possible 
CAA diagnoses were established in (and thus CAA-related ICH prevalence estimated based on) 
a subgroup with ‘complete’ work-up including MRI-SWI and angiography (not allowing CT-
only), increasing diagnostic sensitivity and specificity. 
 
Conclusion 
This study provides an in-depth retrospective analysis of spontaneous ICHs, with 
particular focus on the prevalence and clinical predictors of CAA-related ICH, first in a country 
from this region, and among the few reports previously published in the literature. We conclude 
that CAA-related ICHs are at least as frequent (14.7%) in our population as reported 
internationally (5-20%). Notably, the remarkably low rate of clinically and radiologically 
established probable CAA diagnosis puts a significant percentage of the population, especially 
the elderly under antiplatelet therapy (as demonstrated), at a high risk of possibly lethal ICHs. 
This highlights the need for an increased awareness of CAA by both neurologists and 
radiologists. 
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Fig. 1 
Flow diagram of the process of identifying spontaneous intracerebral hemorrhages (ICHs) 
 
 
 
Fig. 2 
a) Localization of spontaneous intracerebral hemorrhages (ICHs). b) The distribution of 
underlying etiologies within lobar/cerebellar ICHs 
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Fig. 3 
Representative axial MRI-SWI images of probable CAA patients at different parts of the 
spectrum. a) Diffuse CSS with multiple lobar CMBs and ICHs of different ages. b) Diffuse (but 
less extensive) CSS with a recurrent lobar ICH and a single CMB. c) No CSS but multiple lobar 
CMBs accompanying a recent lobar ICH. The deep structures (i.e., basal ganglia, thalamus, and 
brainstem) are consistently devoid of hemorrhagic pathology 
CAA, cerebral amyloid angiopathy; CMB, cerebral microbleed; CSS, cortical superficial 
siderosis; ICH, intracerebral hemorrhage; MRI, magnetic resonance imaging; SWI, 
susceptibility-weighted imaging.  
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Table 1 Discriminators of spontaneous ICHs with regard to localization 
 
  Lobar/cerebellar Deep MW/Chi2 multivariate logistic regression 
  ICH ICH  p p OR (95%CI) 
Patient number  92 121 - -  
Age at event* y 74.5 [65.9–82.0] 64.7 [57.9–76.6] <0.001 0.014 1.03 (1.01–1.06) 
Sex (male/female) % 52.2 66.9 0.029 >0.05 - 
Prior ischemic stroke % 12.0 12.7 >0.05 - - 
Prior intracranial hemorrhage % 7.7 8.5 >0.05 - - 
Prior TIA (TFNE) % 14.1 7.6 >0.05 - - 
Prior loss of consciousness % 9.8 6.8 >0.05 - - 
Family history for any stroke % 37.5 28.8 >0.05 - - 
Anticoagulant use % 20.9 13.4 >0.05 - - 
INR>1.4 % 18.4 11.4 >0.05 - - 
Antiplatelet use* % 43.3 23.7 0.003 0.043 1.96 (1.02–3.75) 
Combined antithrombotic use % 13.3 3.4 0.016 >0.05 - 
Hypertensive excess* % 48.9 71.2 0.001 0.002 0.39 (0.21–0.71) 
Chronic hypertension % 88.0 90.9 >0.05 - - 
Case fatality (1-month) % 34.8 33.1 >0.05 - - 
 
MW/Chi2, Mann-Whitney test (for Age at event) or Chi2 test (for other variables); CI, 
confidence interval; ICH, intracerebral hemorrhage; INR, international normalized ratio; OR, 
odds ratio; TIA, transient ischemic attack; TFNE, transient focal neurological episode; y, year 
(median [interquartile range]); bold font indicates variables with significant difference in 
univariate analyses; * indicates significant predictors in the multivariate analyses. 
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Table 2 Discriminators of spontaneous ICHs with regard to probable/definite CAA diagnosis 
  Probable/definite Non-probable St/Chi2 multivariate logistic regression 
  CAA CAA p p OR (95%CI) 
Patient number  16 152  -  
Age at event* y 75.9±2.3 65.6±1.1 0.002 0.012 1.08 (1.02–1.15) 
Sex (male/female) % 37.5 64.5 0.035 >0.05 - 
Prior ischemic stroke % 18.8 10.7 >0.05 - - 
Prior intracranial hemorrhage* % 31.3 6.8 0.008 0.005 8.53 (1.94–37.58) 
Prior TIA (TFNE) % 31.3 7.4 0.010 >0.05 - 
Prior loss of consciousness % 18.8 6.0 >0.05 - - 
Family history for any stroke % 42.9 29.1 >0.05 - - 
Anticoagulant use % 18.8 12.8 >0.05 - - 
INR>1.4 % 20.0 10.4 >0.05 - - 
Antiplatelet use* % 56.3 25.2 0.009 0.042 3.45 (1.05–11.38) 
Combined antithrombotic use % 6.4 4.1 >0.05 - - 
Hypertensive excess % 46.7 64.2 >0.05 - - 
Chronic hypertension % 93.8 88.8 >0.05 - - 
Case fatality (1-month) % 31.3 28.9 >0.05 - - 
 
St/Chi2, Student t-test (for Age at event) or Chi2 test (for other variables); CI, confidence 
interval; ICH, intracerebral hemorrhage; INR, international normalized ratio; OR, odds ratio; 
TIA, transient ischemic attack; TFNE, transient focal neurological episode; y, year 
(mean±SEM); bold font: indicates variables with significant difference in univariate analyses; 
* indicates significant predictors in multivariate analyses. 
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Online Resource 1 Neuropathology of definite cerebral amyloid angiopathy (CAA) cases. a) 
Leptomeningeal and penetrating cortical arteries with thickened Congo red-positive walls, 
demonstrating apple-green birefringence under the polarized microscope (insets). b) Immunostaining 
for amyloid-β reveals denegerated vessel walls with typical double-barrel formation, with occasional 
widening of the perivascular space and perivascular amyloid-β deposition (inset). c) Subcortical 
microbleeds with erythrocyte extravasation, hemosiderin deposition, and characteristic central pallor 
with a central arteriole/capillary (often occluded; lower-left inset (Crossmon)), occasionally with 
immunopositivity for amyloid-β (upper-right inset). d) Cortical superficial (i.e., subarachnoid) siderosis 
with apparent siderophage activity (occasionally also laden with diffuse amyloid-β-immunopositive 
material; inset). e) All 3 patients with definite CAA demonstrated different amount of amyloid-β plaque 
pathology in addition to CAA. f) Only 2 of the 3 definite CAA patients showed Tau pathology in the 
examined regions with neurofibrillary tangles and dystrophic neurites (inset), reflecting the ~70% 
overlap with Alzheimer’s disease pathology. 
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Online Resource 2 Predictors of 1-month case fatality in spontaneous ICHs 
 
  Case fatality Alive MW/Chi2 multivariate logistic regression 
  at 1 month at 1 month p p OR (95%CI) 
Patient number  72 138 - - - 
Age at event* y 75.3 [66.4–82.4] 65.4 [56.3–76.8] <0.001 0.003 1.04 (1.01–1.07) 
Sex (male/all) % 65.3 58.0 >0.05 - - 
Localization (deep/all) % 55.6 58.7 >0.05 - - 
Prior ischemic stroke % 15.9 10.9 >0.05 - - 
Prior intracranial hemorrhage % 7.2 8.8 >0.05 - - 
Anticoagulant use % 25.7 11.7 0.010 >0.05 - 
INR>1.4* % 23.6 8.7 0.004 0.035 2.51 (1.07–5.88) 
Antiplatelet use % 29.0 33.8 >0.05 - - 
Combined antithrombotic use % 10.1 5.9 >0.05 - - 
Hypertensive excess % 66.7 60.2 >0.05 - - 
Chronic hypertension % 88.9 89.9 >0.05 - - 
 
MW/Chi2, data obtained from the Mann-Whitney test (for Age at event) or the Chi square test 
(for all other variables); CI, confidence interval; ICH, intracerebral hemorrhage; INR, 
international normalized ratio; OR, odds ratio; TIA, transient ischemic attack; TFNE, transient 
focal neurological episode; y, year (data is presented in median [interquartile range]); bold font 
indicates variables with significant difference in comparative analyses; * indicates significant 
predictors in the model controlling for all variables significant in the comparative analyses. 
Three cases were excluded from the analyses due to unrelated cause of death, as per definition. 
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Online Resource 3 Overview of studies reporting CAA-related ICH prevalence on clinical grounds. 
The studies are separated based on whether they reported subgroups of CAA diagnosis or not. 
 Jamieson 2012 [1]
a Meretoja 2012 [2] 
SMASH-U 
Palm 2013 [3] 
semi-SMASH-Ua 
Roh 2018 [4] 
semi-SMASH-Ua 
Present study 
definite CAA 0 0.0% 10 4.9% 0 0.0% 2 2.0% 3 11.5% 
supportive histopathology for CAA 0 0.0% 2 1.0% 0 0.0% 6 6.0% 0 0.0% 
probable CAA 6 11.3% 36 17.6% 15 34.1% 47 46.5% 13 50.0% 
possible CAA 47 88.7% 157 76.6% 29 65.9% 46 45.5% 10 38.5% 
all ICHs (spontaneous) 136  1013  152  425  213  
all CAAs / all ICHs 53 39.0% 205 20.2% 44 28.9% 101 23.8% 26/47/92 23.9%c 
probable-definite CAAs / all ICHs 6 4.4% 48 4.7% 15 9.9% 55 12.9% 16/47/92 14.7%c 
MRI / all ICHs NA  15.1%  20.4%  NA  37.1%  
MRI / all CAAs NA  20.5%  NA  71.3%b  96.2%d  
SWI / all ICHs NA  NA  NA  NA  31.0%  
SWI / CAAs NA  NA  NA  NA  92.3%d  
angiography / all ICHs NA  25%  26.3%  NA  55.4%  
angiography / all CAAs NA  NA  NA  NA  100.0%  
cerebellar ICHs excluded from CAA yes  yes  yes  no  no  
           
           
 Yeh 2014 [5] 
SMASH-U 
Cappellari 2015 [6] 
semi-SMASH-Ue 
Owolabi 2017 [7] 
SMASH-U 
Wu 2017 [8] 
SMASH-U 
Forlivesi 2018 [9] 
SMASH-U 
definite CAA NA  NA  NA  NA  NA  
supportive histopathology for CAA NA  NA  NA  NA  NA  
probable CAA NA  NA  NA  NA  NA  
possible CAA NA  NA  NA  NA  NA  
all CAAs / all ICHs 463 12.2% 62 14.6% 1 2.4% 344 23.7% 51 16.6% 
all ICHs (spontaneous) 3785  424  42  1452  308  
probable-definite CAA / all ICHs NA  NA  NA  NA  NA  
MRI / all ICHs NA  NA  NA  NA  NA  
MRI / all CAAs NA  NA  NA  NA  NA  
SWI / all ICHs NA  NA  NA  NA  NA  
SWI / CAAs NA  NA  NA  NA  NA  
angiography / all ICHs 25.0%  NA  NA  NA  NA  
angiography / all CAAs 39.1%  NA  NA  NA  NA  
cerebellar ICHs excluded from CAA yes  no  yes  yes  yes  
 
CAA, cerebral amyloid angiopathy, ICH, intracerebral hemorrhage; MRI, magnetic resonance imaging; NA, not available; SWI, susceptibility-
weighted imaging;  
a structural etiologies not included (i.e., primary ICHs only) 
b all probable/supported/definite CAA but 3 had MRI (SWI rate undisclosed); those without MRI had supportive intraoperative histology. 
c data extrapolated from the rate within adequately worked-up lobar/cerebellar ICHs (i.e., MRI-SWI and angiography or neuropathology required), as 
detailed in the manuscript. 
d all probable/definite CAA but 1 had MRI and all but 2 had SWI; those without MRI/SWI had definite CAA diagnosis post mortem. 
e brainstem ICH was allowed in CAA. 
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Online Resource 4 Discriminators of spontaneous ICHs with regard to lobar vs. non-lobar 
localization 
 
    MW/Chi2 multivariate logistic regression 
  Lobar ICH Non-lobar ICH  p p OR (95%CI) 
Patient number  85 128 - -  
Age at event* y 74.7 [66.2–82.2] 64.9 [57.8–76.6] <0.001 0.006 1.04 (1.01–1.06) 
Sex (male/female) % 52.9 65.6 >0.05 - - 
Prior ischemic stroke % 12.9 12.0 >0.05 - - 
Prior intracranial hemorrhage % 8.3 8.0 >0.05 - - 
Prior TIA (TFNE) % 15.3 7.2 >0.05 - - 
Prior loss of consciousness % 10.6 6.4 >0.05 - - 
Family history for any stroke % 37.8 29.0 >0.05 - - 
Anticoagulant use % 20.2 14.3 >0.05 - - 
INR>1.4 % 17.3 12.5 >0.05 - - 
Antiplatelet use* % 44.6 24.0 0.002 0.041 1.97 (10.3–3.76) 
Combined antithrombotic use % 13.3 4.0 0.018 >0.05 - 
Hypertensive excess* % 48.2 70.4 0.001 0.003 0.39 (0.21–0.72) 
Chronic hypertension % 88.2 90.6 >0.05 - - 
Case fatality (1-month) % 35.3 32.8 >0.05 - - 
 
MW/Chi2, Mann-Whitney test (for Age at event) or Chi2 test (for other variables); CI, 
confidence interval; ICH, intracerebral hemorrhage; INR, international normalized ratio; OR, 
odds ratio; TIA, transient ischemic attack; TFNE, transient focal neurological episode; y, year 
(median [interquartile range]); bold font indicates variables with significant difference in 
univariate analyses; * indicates significant predictors in the multivariate analyses. 
 
